European Journal of Cancer
Volume 44, Issue 6 , Pages 819-829 , April 2008

Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy

  • J.H. Schouwink

      Affiliations

    • Medisch Spectrum Twente, Department of Pulmonology, Haaksbergerstraat 55, 7513 ER Enschede, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 (0) 53 4 87 26 21; fax: +31 (0) 53 4 87 26 38.
    • ,
  • H. Codrington

      Affiliations

    • HAGA Ziekenhuizen, Lokatie Leyenburg, Department of Pulmonology, Den Haag, The Netherlands
    • ,
  • H.P. Sleeboom

      Affiliations

    • HAGA Ziekenhuizen, Lokatie Leyenburg, Department of Internal Medicine, Den Haag, The Netherlands
    • ,
  • L.G.M. Kerkhofs

      Affiliations

    • Ziekenhuis Walcheren, Department of Internal Medicine, Vlissingen, The Netherlands
    • ,
  • L.W. Wormhoudt

      Affiliations

    • Ortho Biotech, A division of Janssen-Cilag B.V., Department of Medical Affairs, Tilburg, The Netherlands

Received 28 November 2007 ,Revised 8 February 2008 ,Accepted 14 February 2008.

References 

  1. Groopman JE, Itri LM. Chemotherapy-induced anaemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–1634
  2. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293–2306
  3. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258–270
  4. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III randomized, double-blind study of epoetin alfa compared with placebo in anaemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606–2617
  5. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JWR. Epoetin alfa treatment results in clinically significant improvements in quality of life in anaemic cancer patients when referenced to the general population. J Clin Oncol. 2003;21:366–373
  6. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in haemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875–2882
  7. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B for the Epoetin Alfa Study Group. Effects of epoetin alfa on haematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  8. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218–1234
  9. Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer. 2002;87:1341–1353
  10. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172–179
  11. Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin alfa corrects anaemia and improves quality of life in patients with haematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol. 2003;21:169–180
  12. Demetri GD, Kris M, Wade J, Degos L, Cella D for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412–3425
  13. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in haemoglobin level and quality of life during chemotherapy in anaemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–895
  14. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132–149
  15. Hudis CA, Vogel CL, Gralow JR, Williams D and the Procrit Study Group. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer. 2005;6:132–142
  16. Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P for the EPO-INT-45 Study Group. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer. 2006;94:947–954
  17. Pronzato P, Cortesi E, van der Rijt C, et al. Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group). Ann Oncol. 2002;13(Suppl. 5):168;[abstract 6200]
  18. Crawford J, Robert F, Perry M, Belani CP, Sarokhan B for the Anaemia Prevention in NSCLC Study Group. Epoetin alfa 40,000U once weekly maintains haemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy. Proc Am Soc Clin Oncol. 2003;22:628;[abstract 2527]
  19. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains haemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23:2597–2605
  20. Milroy R, Scagliotti G, van den Berg PM, et al. Early intervention with Epoetin alfa maintains haemoglobin (Hb) in advanced non-small-cell lung cancer (NSCLC) patients. Lung Cancer. 2003;41:S74;[abstract O-253]
  21. Savonije JH, van Groeningen CJ, van Bochove A, et al. Effects of early intervention with epoetin alfa on transfusion requirement, haemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer. 2005;41:1560–1569
  22. Richart JM, Petruska PJ, Klebert KS, et al. A Phase III trial of Epoetin-alfa: early vs late administration in patients treated with chemotherapy. Blood. 2002;100:175b;[abstract 4199]
  23. Straus DJ, Testa MA, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anaemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for haematologic malignancies. Cancer. 2006;107:1909–1917
  24. Crawford J, Robert F, Perry M, Belani C, Williams D Anemia Prevention in NSCLC Group. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol. 2007;2:210–220
  25. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006;106:223–233
  26. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714
  27. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083–4107
  28. Charu V, Saidman B, Ben-Jacob A, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007;12:1253–1263

PII: S0959-8049(08)00129-9

doi: 10.1016/j.ejca.2008.02.017

European Journal of Cancer
Volume 44, Issue 6 , Pages 819-829 , April 2008

Article Tools

* Image Usage & Resolution